91 related articles for article (PubMed ID: 17053815)
1. CD4+CD25+ regulatory T-cell-inactivation in combination with adenovirus vaccines enhances T-cell responses and protects mice from tumor challenge.
Elia L; Aurisicchio L; Facciabene A; Giannetti P; Ciliberto G; La Monica N; Palombo F
Cancer Gene Ther; 2007 Feb; 14(2):201-10. PubMed ID: 17053815
[TBL] [Abstract][Full Text] [Related]
2. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
[TBL] [Abstract][Full Text] [Related]
3. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Aarts WM; Schlom J; Hodge JW
Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
[TBL] [Abstract][Full Text] [Related]
4. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer.
Saha A; Chatterjee SK
Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
6. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
7. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
Kudo-Saito C; Schlom J; Hodge JW
Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693
[TBL] [Abstract][Full Text] [Related]
8. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.
Mortara L; Frangione V; Castellani P; De Lerma Barbaro A; Accolla RS
Int Immunol; 2009 Jun; 21(6):655-65. PubMed ID: 19395374
[TBL] [Abstract][Full Text] [Related]
9. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.
Conforti A; Peruzzi D; Giannetti P; Biondo A; Ciliberto G; La Monica N; Aurisicchio L
J Immunother; 2009 Sep; 32(7):744-54. PubMed ID: 19561534
[TBL] [Abstract][Full Text] [Related]
10. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing.
Chakraborty M; Abrams SI; Coleman CN; Camphausen K; Schlom J; Hodge JW
Cancer Res; 2004 Jun; 64(12):4328-37. PubMed ID: 15205348
[TBL] [Abstract][Full Text] [Related]
11. Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response.
Delluc S; Hachem P; Rusakiewicz S; Gaston A; Marchiol-Fournigault C; Tourneur L; Babchia N; Fradelizi D; Regnault A; Sang KH; Chiocchia G; Buzyn A
Cancer Immunol Immunother; 2009 Oct; 58(10):1669-77. PubMed ID: 19225777
[TBL] [Abstract][Full Text] [Related]
12. Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells.
Degl'Innocenti E; Grioni M; Capuano G; Jachetti E; Freschi M; Bertilaccio MT; Hess-Michelini R; Doglioni C; Bellone M
Cancer Res; 2008 Jan; 68(1):292-300. PubMed ID: 18172322
[TBL] [Abstract][Full Text] [Related]
13. Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells.
Nagayama Y; Hase W; Motoyoshi Y; Saitoh O; Sogawa R; Nakao K
Oncol Rep; 2007 May; 17(5):1269-73. PubMed ID: 17390075
[TBL] [Abstract][Full Text] [Related]
14. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM
J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540
[TBL] [Abstract][Full Text] [Related]
15. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
16. CD8+ T-cell tolerance can be broken by an adenoviral vaccine while CD4+ T-cell tolerance is broken by additional co-administration of a Toll-like receptor ligand.
Salucci V; Mennuni C; Calvaruso F; Cerino R; Neuner P; Ciliberto G; La Monica N; Scarselli E
Scand J Immunol; 2006 Jan; 63(1):35-41. PubMed ID: 16398699
[TBL] [Abstract][Full Text] [Related]
17. Accelerating the secondary immune response by inactivating CD4(+)CD25(+) T regulatory cells prior to BCG vaccination does not enhance protection against tuberculosis.
Quinn KM; Rich FJ; Goldsack LM; de Lisle GW; Buddle BM; Delahunt B; Kirman JR
Eur J Immunol; 2008 Mar; 38(3):695-705. PubMed ID: 18266274
[TBL] [Abstract][Full Text] [Related]
18. Adoptive transfer of transplantation tolerance mediated by CD4+CD25+ and CD8+CD28- regulatory T cells induced by anti-donor-specific T-cell vaccination.
Wang J; Zhang L; Tang J; Jiang S; Wang X
Transplant Proc; 2008 Jun; 40(5):1612-7. PubMed ID: 18589160
[TBL] [Abstract][Full Text] [Related]
19. CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma.
Johnson BD; Jing W; Orentas RJ
J Immunother; 2007; 30(2):203-14. PubMed ID: 17471167
[TBL] [Abstract][Full Text] [Related]
20. Increased CD4+CD25+Foxp3+ regulatory T cells in tolerance induced by portal venous injection.
He F; Chen Z; Xu S; Cai M; Wu M; Li H; Chen X
Surgery; 2009 Jun; 145(6):663-74. PubMed ID: 19486771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
